Seattle Genetics, an emerging multi-product, global biotechnology company, develops and commercializes transformative cancer-targeting therapies. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. We have a robust pipeline of novel targeted therapies to address significant unmet needs. We are based in the US, with European operations in Switzerland.